- $568.60m
- -$385.20m
- $263.40m
- 34
- 52
- 47
- 41
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.86 | ||
| Price to Tang. Book | 0.86 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 1.33 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -12.15% | ||
| Return on Equity | -7.34% | ||
| Operating Margin | -22.39% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 21.8 | 46.7 | 131.4 | 78.5 | 263.4 | 277.79 | 141.59 | 43.71% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Arvinas, Inc. is a clinical-stage biotechnology company. The Company, through its PROteolysis Targeting Chimera (PROTAC) protein degrader platform, is pioneering the development of protein degradation therapies designed to harness the body’s natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It is progressing multiple investigational drugs through clinical development programs, including vepdegestrant, ARV-393 and ARV-102. Vepdegestrant is an investigational orally bioavailable PROTAC protein degrader designed to target and degrade the ER for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. It is co-developing vepdegestrant with Pfizer. ARV-393 is an investigational, orally bioavailable PROTAC designed to degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. ARV-102 is in development to treat neurodegenerative diseases.
Directors
- Timothy Shannon NEC (62)
- John Houston PRE (61)
- Sean Cassidy CFO (51)
- Ian Taylor CSO (58)
- Ronald Peck OTH (55)
- Linda Bain DRC (50)
- Wendy Dixon IND (65)
- Edward Kennedy IND (59)
- Bradley Margus IND (60)
- Briggs Morrison IND (62)
- Leslie Norwalk IND (55)
- Liam Ratcliffe IND (57)
- Laurie Smaldone Alsup IND (67)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- December 9th, 2014
- Public Since
- September 27th, 2018
- No. of Shareholders
- 23
- No. of Employees
- 430
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 72,991,390
- Address
- 5 Science Park, NEW HAVEN, 06511-1966
- Web
- https://www.arvinas.com/
- Phone
- +1 2035351456
- Auditors
- Deloitte & Touche LLP
Upcoming Events for ARVN
Q3 2025 Arvinas Inc Earnings Release
Similar to ARVN
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Arvinas share price?
As of Today at 19:20 UTC, shares in Arvinas are trading at $7.79. This share price information is delayed by 15 minutes.
How has the Arvinas share price performed this year?
Shares in Arvinas last closed at $7.79 and the price had moved by -72.78% over the past 365 days. In terms of relative price strength the Arvinas share price has underperformed the S&P500 Index by -75.58% over the past year.
What are the analyst and broker recommendations for Arvinas?
The overall consensus recommendation for Arvinas is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Arvinas dividend yield?
Arvinas does not currently pay a dividend.
Does Arvinas pay a dividend?
Arvinas does not currently pay a dividend.
When does Arvinas next pay dividends?
Arvinas does not currently pay a dividend.
How do I buy Arvinas shares?
To buy shares in Arvinas you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Arvinas?
As of the previous close price of $7.79, shares in Arvinas had a market capitalisation of $568.60m.
Where are Arvinas shares listed?
Here are the trading details for Arvinas:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: ARVN
What kind of share is Arvinas?
Based on an overall assessment of its quality, value and momentum Arvinas is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Arvinas share price forecast for 2025?
The analyst consensus target price for shares in Arvinas is $14.03. That is 80.1% above the last closing price of $7.79.
Analysts covering Arvinas currently have a consensus Earnings Per Share (EPS) forecast of -$1.50 for the next financial year.
Find out moreWhat is the trend in the Arvinas share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Arvinas. Over the past six months, its share price has underperformed the S&P500 Index by -60.99%.
As of the last closing price of $7.79, shares in Arvinas were trading -50.72% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Arvinas PE Ratio?
The Arvinas PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $7.79.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Arvinas?
Arvinas' management team is headed by:
- Timothy Shannon - NEC
- John Houston - PRE
- Sean Cassidy - CFO
- Ian Taylor - CSO
- Ronald Peck - OTH
- Linda Bain - DRC
- Wendy Dixon - IND
- Edward Kennedy - IND
- Bradley Margus - IND
- Briggs Morrison - IND
- Leslie Norwalk - IND
- Liam Ratcliffe - IND
- Laurie Smaldone Alsup - IND